ClinicalTrialsFinder

Prostate Adenocarcinoma With Neuroendocrine Differentiation Clinical Trials in Tianjin, Tianjin Municipality

1 recruitingTianjin, Tianjin Municipality, China

Showing 1–1 of 1 trials

Recruiting
Phase 2

Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

Prostate Cancer (Adenocarcinoma)Prostate Cancer Metastatic Castration-ResistantProstate Adenocarcinoma With Neuroendocrine Differentiation
Tianjin Medical University Second Hospital28 enrolled1 locationNCT07179783